Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 35303070

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2022 May 26
First author
Song Y

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 May 26;139(21):3103-3104. doi: 10.1182/blood.2022015995.
    note
    Source null
    related pmid
    35616990
    relationship
    Comment in

Authors and identifiers

  1. name
    Song Y
    type
    Author
  2. name
    Zhou K
    type
    Author
  3. name
    Zou D
    type
    Author
  4. name
    Zhou J
    type
    Author
  5. name
    Hu J
    type
    Author
  6. name
    Yang H
    type
    Author
  7. name
    Zhang H
    type
    Author
  8. name
    Ji J
    type
    Author
  9. name
    Xu W
    type
    Author
  10. name
    Jin J
    type
    Author
  11. name
    Lv F
    type
    Author
  12. name
    Feng R
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Song Y
    type
    Author
  2. name
    Zhou K
    type
    Author
  3. name
    Zou D
    type
    Author
  4. name
    Zhou J
    type
    Author
  5. name
    Hu J
    type
    Author
  6. name
    Yang H
    type
    Author
  7. name
    Zhang H
    type
    Author
  8. name
    Ji J
    type
    Author
  9. name
    Xu W
    type
    Author
  10. name
    Jin J
    type
    Author
  11. name
    Lv F
    type
    Author
  12. name
    Feng R
    type
    Author
bibliography ids
  1. nci-bib-42d99fd96e30e44c84c3b3d5
book metadata
content sha256
01e3e56a3f9e79621e9527908f8a5b902ad42159b5083efae29bd1291437d65d
document type
citation
dois
  1. 10.1182/blood.2021014162
electronic publication date
display
Source null
precision
missing
year
Source null
evidence scope
bibliographic_metadata_only
id
pubmed:35303070
immutable id
pubmed:35303070@01e3e56a3f9e79621e9527908f8a5b902ad42159b5083efae29bd1291437d65d
journal
abbreviation
Blood
issn electronic
1528-0020
issn print
0006-4971
issue
21
name
Blood
nlm unique id
7603509
pages
3148-3158
volume
139
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Blood. 2022 May 26;139(21):3103-3104. doi: 10.1182/blood.2022015995.
    note
    Source null
    related pmid
    35616990
    relationship
    Comment in
outcomes validated
false
pmid
35303070
provenance
batch id
3f4d1914d2afe41e9e70
provider
NCBI PubMed ESummary
record sha256
6156f992faeecc75d01089e25c9122ae9a2cc3170c305593285cba8d75447efb
response sha256
0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
retrieved at
2026-09-09T23:48:06.522634+00:00
publication date
display
2022 May 26
precision
day
year
2022
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/35303070/
title
Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study.

Preserved source evidence · Not medical advice